Progressive Myoclonic Epilepsies - A Pragmatic Review

Area of Science:

• Neurology
• Genetics
• Neurodegenerative Diseases

Background:

• Progressive Myoclonus Epilepsy (PME) encompasses rare, inherited neurodegenerative disorders.
• Key features include myoclonus, cognitive decline, seizures, and ataxia.
• Molecular diagnoses are available for approximately 80% of PME cases.

Purpose of the Study:

• To review clinical phenotypes, genotypes, and management strategies for PME.
• To explore prevalent and newly identified PME forms for improved clinical evaluation.
• To suggest management approaches for this challenging condition.

Main Methods:

• Literature search of PME publications over the past 20 years, focusing on the last decade.
• Databases searched include Medline, JSTOR, and PubMed.

Main Results:

• PME symptom progression varies significantly among individuals.
• Major PME syndromes include Lafora Disease, Unverricht-Lundborg Disease (EPM1), Myoclonic Epilepsy with Ragged-Red Fibers (MERRF), and Neuronal Ceroid Lipofuscinoses (NCL).
• Clinical and EEG findings aid in differentiating PME etiologies.

Conclusions:

• Anticonvulsant medications like valproic acid and perampanel are used for seizure management.
• Despite treatment, PME often follows a progressive course with potential treatment resistance.
• Understanding genetic factors and clinical features is crucial for effective PME management.